Thank you for submitting your manuscript for consideration by The EMBO Journal. Three expert referees have now evaluated it, and their reports are copied below. Given that two referees are in principle supportive, we would be open to consider a revised manuscript further for publication in our journal. Nevertheless, the reports raise a number of substantive points that would in our opinion need to be satisfactorily addressed before publication would be warranted. The most significant of those is to provide better insight into the recruitment mechanism and interdependencies of ERalpha and JMJD3 (see referee 1 point 2, referee 2 point 3); given that chromatin alterations in transcriptional activation do not per se constitute a novel concept, we feel that such further understanding will be essential to publication in a broad general journal. Furthermore, other major points needing to be addressed with additional data would be points 3 and 4 by referee 1, point 1 of referee 2 to also look at proliferation, and points 9 and 10 as well as the more specific control requests by referee 3. In contrast, we feel that several other points will not need further experimental data but should nevertheless be diligently discussed (referee 1 points 5 & 6, referee 2 point 2 and related point 4 of referee 3, and referee 3's points 6, 11 and 13). Finally, please follow the referees suggestions regarding presentational and editorial issues.
Should you be able to improve the manuscript along these lines, we should be able to consider a revised manuscript further for publication. I have to add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The manuscript by Svotelis et al described their investigation on the role of JMJD3, a H3K27-specific demethylase, in the apoptosis and anti-estrogen resistance of breast cancer cells. While the subject matter is fairly important, the current manuscript lacks a blend of depth and breadth, is short of appropriate controls and mechanistic insights, is with data that were mis-or over-interpreted, and is with confusing arguments, thus adding little to the current understanding of either estrogen receptor-mediated gene transcription or anti-estrogen resistance in breast cancer.
Specific comments:
1) That Bcl-2 is a target for estrogen receptor in breast cancer is well established, and surely, gene expression involves epigenetic regulation, including H3K27me3 demethylation. In the opinion of this reviewer, the current study lacks a sufficient lovelty that is appropriate for this journal.
2) JMJD3 is involved in ER-mediated Bcl-2 transcription is interesting, though not unexpected, as stated above. However, one of the major problems associated with this manuscript is that it lacks a mechanistic insight into the E2-dependent recruitment of JMJD3. The authors ought to demonstrate, by molecular and biochemical approaches for example, that how JMJD3 is recruited by ERalphamediated transcription initiation complex. Is JMJD3 recruited by ERalpha through physical interaction between ERalpha and JMJD3 or through physical interaction between one of the component of ERalpha-mediated transcription initiation complex and JMJD3. Without this data, it is hard to understand how JMJD3 plays a role in E2-dpendent gene transcription, and it is inappropriate to argue that JMJD3 colocalised with ERalpha at both the active P1 promoter and the ERE enhancer regions of Bcl-2 ( Figure 3C ). It is even confusing to argue that localization of JMJD3 and ERalpha at the enhancer region of BCL2 are "co-dependent" (Fig. 4E and 4F ), as the authors argued earlier that the recruitment and the action of JMJD3 are regulated in an ERalpha liganddependent manner (Fig. 4B) , which is plausible. However, to argue that the recruitment of ERalpha is dependent on JMJD3 simply does not make any sense.
3) Some of the key observations need to be verified at least in another ERalpha positive breast cancer cell line. 4) To make the conclusion that "specific depletion of JMJD3 by shRNA-mediated knockdown blocked the ERalpha-dependent activation of BCL2 expression in MCF7 cells in an ERalpha-specific manner" ( Figure 2D -E), the authors need to knockdown the expression of ERalpha and perform the experiments.
5) The latter portion of the manuscript describing the nongenomic action of ERalpha is confusing and somewhat contradict to the former portion of the manuscript. First, the experiments in this part are largely dependent on artificial systems such as MCF7/LCC2 (LCC2), MCF7/LCC9 (LCC9), and MCF7/HER2-18. Therefore, the pathophysiological relevance of the observations described in this manuscript is in question. Secondly, the main argument of the latter part is that inactivation of EZH2 methyltransferase activity by non-genomic pathways controls BCL2 transcription and apoptosis in AE-sensitive and AE-resistant breast cancer. Yet the main argument of the former part is the JMJD3 is the key player in BCL2 transcription. EZH2 is the writer of H3K27me3 and JMJD3 is the eraser of this mark. So the question is exactly what is the key: the writer or the eraser or both.
6) It is probably more appropriate to investigate the global gene expression in MCF7 cells depleted or not of JMJD3 with ChIP deep sequencing.
Referee #2 (Remarks to the Author):
This is a great story that is set around a close-up view of the internal Bcl2 gene enhancer. The equilibrium between the action of the H3K27 methylase EZH2 and the demethylase JMJD3 at the ER target site controls the hormonal response and thus survival of breast cancer cells. Under conditions that shift this equilibrium towards the demethylated state and thus Bcl2 expression, cells become resistant to tamoxifen, at least they don't die anymore. This study is very nicely and comprehensively done, and the newly discovered link is highly original and of potentially great physiological/pathological significance. As far as experiments go, I do not have any criticism. However, I do need to raise some points regarding the interpretation and discussion of results.
Major comments:
(1) H3K27 methylation and ER ligand-dependence: whereas this paper very convincingly demonstrates a link for the Bcl2 gene and for tamoxifen-induced or estrogen (E2)-inhibited apoptosis, it does not show that E2-induced proliferation involves this system. Hence, statements such as the one in the first sentence of the Results or the last of the Abstract are not justified. Yes, functional inactivation of EZH2, for example, renders cells tamoxifen-resistant in terms of apoptosis. However, tamoxifen resistance is more than just absence of death. One wonders for example whether the cells also proliferate in a tamoxifen-resistant fashion? Doing the experiment is not absolutely necessary, but being more cautious with the conclusions is.
(2) Related to comment #1 is the fact that the JMJD3 knockdown (Fig. 2B) does not abolish the ER hormonal responses! The basals are lower, but the fold-inductions seem pretty similar. Thus, the response of the Bcl2 gene to manipulations of the H3K27 methylation system (Fig. 2D ) seems rather unique amongst the ER target genes. It is conceivable that many if not most ER target genes still respond to E2 albeit in a somewhat altered way because of more general changes in chromatin. (3) Mechanism of JMJD3 recruitment by ER (or vice-versa): apart from the interdependence, the mechanism remains unexplored. While that may be acceptable at this point, it is hard to understand why the mechanism that has been proposed for the action of another demethylase, LSD1, a few residues N-terminal in H3, is not discussed. The paper by Avvedimento and colleagues (Perillo et. 2008 ) is extensively cited, but never for this key contribution.
Minor comments:
(4) References in Introduction, at least regarding ER and breast cancer, seem somewhat random (many are not directly related to the statements and too many reviews are not sufficiently recent). (5) Results, first subtitle: careful, it's not cancer but cancer cell lines (in fact, only one). (6) Page 9, bottom: the "surrounding binding region" is a weird term.
Referee #3 (Remarks to the Author):
The authors have written an elegant paper, illustrating the role of JMJD3 in H3K27 demethylation as a causal player in BCL-2 expression after E2 treatment, which is presented as a key event in E2-mediated apoptosis prevention. The quality and quantity of the presented work gives the impression that this piece of research has gone through quite a history of revisions, and could be considered as 'impressive'. Even though I do like the story, there are some issues I would like to see altered/discussed/revised.
1.The paper is written in quite a 'verbose' style, which makes reading it significantly more complex then necessary. Special attention should be focussed on the text describing figure 5 as well as the discussion. Referencing of some data and the figures it belongs to is not always logically written (e.g. the description of figure S1 ). 2. For all bar graphs throughout the manuscript, proper statistics should be included, and p values stated in the figure legends. Figure S4 and S5 lack standard deviations, and Figure S8 lacks any quantification. This should be included. 3. The expression array data as described in in Figure 2A should be part of the manuscript and not only limited to a list of overlapping genes as a supplementary table. 4.In Figure 2B , the fold-increase for -E2 vs +E2 seems to be the same when comparing shCTL and shJMJD3, which raises the issue of normalization. The authors should include an ICI treatment for both conditions, illustrating that the differences observed between the shJMJD3 and control are indeed limiting E2 response. 5.This reviewer does not see the added value of Figure 2C , which I think could be removed. 6. The experiments in Figure 3 are very convincing, but lack one set of data. I would like to see included in Figure 3 ChIPs of H3K27me1 and me2. Since JMJD3 converts H3K27me3, any loss of me3 signal should be explained by a gain of me1 and/or me2. 7. Figure 4A shows a loss of ERalpha ChIP signal after 45minutes. Other reports which are cited in this paper (Shang et al., 2000; Metivier et al., 2003) have shown convincingly strong ER ChIP signal at this timepoint. This inconsistency should be discussed. 8. The authors claim that there is no temporal difference observed between ERalpha and JMJD3 recruitment ( Figure 4A ). The temporal resolution of the experimental setup simply does not allow such a statement to be made, even though Figure 4B and 4E do make such a conclusion tempting. I do feel that the statement as written here is stated to strong for the data at hand, and should be weakened. 9. Figure 5 describes the clinical data, where TMAs were stained for Her2 and H3K27me3. Survival data should be included here. This is a very important point. 10. Does the Akt inhibitor revert the resistance-phenotype of of the LCC2 cells? A cell proliferation assay, including LCC2 and MCF7 cells, is needed to illustrate this. 11. Chemical inhibitors do not always tend to be fully specific. Key experiments with the LY294002 inhibitor should be reproduced with another Akt inhibitor. 12. Figure 7 should get a proper figure legend, explaining the model. 13. Akt has been extensively reported to directly influence ERalpha through phosphorylation events on the receptor. Even though I think it's out of the scope of the paper to rule out possible direct effects of Akt on ERalpha through the use of ERalpha point mutants, a direct effect of Akt on ER activity and the possible implications for this paper should be discussed. 14. The reference 'Anderton et al.,' on page 20 lacks a year. We thank all the reviewers for their constructive comments and suggestions that have improved the presentation. As recounted below, we have included experiments as requested by the reviewers and all other minor changes requested. We hope that these revisions will be satisfactory. Response: We believe this to be a very valid point, and we have performed new molecular and biochemical experiments to obtain further insight into the recruitment of JMJD3 by ER (see new Figure 4G -I). Not only does this point reinforce the idea of co-dependent recruitment of ER and JMJD3 at the BCL2 enhancer region, these new results (combined with our previous ChIP experiments ( Figure 3 and 4) confirm that JMJD3 colocalizes with ER by a direct interaction via the AF1 domain of ER Interestingly, these results suggest that the interaction between JMJD3 and the AF1 domain of ER is ligand-independent.
3) Some of the key observations need to be verified at least in another ERalpha positive breast cancer cell line.
Response: We performed apoptosis analysis and quantified the expression of the BCL2 gene in T47D breast cancer cells following the knockdown of JMJD3 in the absence or presence of estrogen (new Figure S2A and S2B), confirming the results we had in MCF7 cells.
4) To make the conclusion that "specific depletion of JMJD3 by shRNA-mediated knockdown blocked the ERalpha-dependent activation of BCL2 expression in MCF7 cells in an ERalpha-specific manner" (Figure 2D-E), the authors need to knockdown the expression of ERalpha and perform the experiments.
Response: These experiments have been performed and added in the new Figure S4A and B. However, to knockdown ER , we used the ICI 180782, a pure antiestrogen that reduces specifically the cellular content of ER in MCF7 cells. Our results show that there is no cumulative effect of ICI treatment and JMJD3 knockdown, suggesting that JMJD3 and ER work in the same pathway to regulate BCL2 expression.
5) The latter portion of the manuscript describing the nongenomic action of ERalpha is confusing and somewhat contradict to the former portion of the manuscript. First, the experiments in this part are largely dependent on artificial systems such as MCF7/LCC2 (LCC2), MCF7/LCC9 (LCC9), and MCF7/HER2-18. Therefore, the pathophysiological relevance of the observations described in this manuscript is in question. Secondly, the main argument of the latter part is that inactivation of EZH2 methyltransferase activity by non-genomic pathways controls BCL2 transcription and apoptosis in AE-sensitive and AEresistant breast cancer. Yet the main argument of the former part is the JMJD3 is the key player in BCL2 transcription. EZH2 is the writer of H3K27me3 and JMJD3 is the eraser of this mark. So the question is exactly what is the key: the writer or the eraser or both.
Response: We clarified this point in the discussion.
6) It is probably more appropriate to investigate the global gene expression in MCF7 cells depleted or not of JMJD3 with ChIP deep sequencing.
Response: Although this is a valid point, it is not the scope of this present study. It would be interesting to pursue this further in the future.
Referee 2 Comments for the authors This is a great story that is set around a close-up view of the internal Bcl2 gene enhancer. The equilibrium between the action of the H3K27 methylase EZH2 and the demethylase JMJD3 at the ER target site controls the hormonal response and thus survival of breast cancer cells. Under conditions that shift this equilibrium towards the demethylated state and thus Bcl2 expression, cells become resistant to tamoxifen, at least they don't die anymore. This study is very nicely and comprehensively done, and the newly discovered link is highly original and of potentially great physiological/pathological significance. As far as experiments go, I do not have any criticism. However, I do need to raise some points regarding the interpretation and discussion of results.

Major comments (1) H3K27 methylation and ER ligand-dependence: whereas this paper very convincingly demonstrates a link for the Bcl2 gene and for tamoxifen-induced or estrogen (E2)-inhibited apoptosis, it does not show that E2-induced proliferation involves this system. Hence, statements such as the one in the first sentence of the Results or the last of the Abstract are not justified. Yes, functional inactivation of EZH2, for example, renders cells tamoxifen-resistant in terms of apoptosis. However, tamoxifen resistance is more than just absence of death. One wonders for example whether the cells also proliferate in a tamoxifen-resistant fashion? Doing the experiment is not absolutely necessary, but being more cautious with the conclusions is.
Response: We agree with this point and changes have been made in the text. Furthermore, as we have shown that the functional inactivation of EZH2 causes a decrease in apoptosis in MCF7 cells in the presence of tamoxifen, we also verify the effect on cellular proliferation in the same conditions. The results that we have obtained clearly corroborate our apoptosis analysis and show that the inactivation of the EZH2 methyltransferase activity increases cell proliferation in presence of tamoxifen as compared to control and EZH2 overexpression ( Figure S10B ).
(2) Related to comment #1 is the fact that the JMJD3 knockdown (Fig. 2B) 
does not abolish the ER hormonal responses! The basals are lower, but the fold-inductions seem pretty similar. Thus, the response of the Bcl2 gene to manipulations of the H3K27 methylation system (Fig. 2D) seems rather unique amongst the ER target genes. It is conceivable that many if not most ER target genes still respond to E2 albeit in a somewhat altered way because of more general changes in chromatin.
Response: This is an interesting point and we agree that it is possible that the BCL2 gene may represent a unique regulation by JMJD3 and H3K27me3. However, this result may be caused by the promoter/enhancer configuration of BCL2 gene and that BCL2 is poised for transcription as compared to some genes investigated in Figure 2B . To illustrate the difference that the referee 3 also mentions, we verified the effect of the depletion of ER using ICI182780 on the expression profile of BCL2 in both control and shJMJD3-treated MCF7 cells (new Figure S4) . The results suggest that JMJD3 is indeed limiting in the E2 response.
(3) Mechanism of JMJD3 recruitment by ER (or vice-versa) : apart from the interdependence, the mechanism remains unexplored. While that may be acceptable at this point, it is hard to understand why the mechanism that has been proposed for the action of another demethylase, LSD1, a few residues N-terminal in H3, is not discussed. The paper by Avvedimento and colleagues (Perillo et. 2008 ) is extensively cited, but never for this key contribution.
Response: As also asked by the referee 1, we have performed new molecular and biochemical experiments to obtain further insight into the recruitment mechanism and interdependencies of ER and JMJD3 ( Figure 4G-I) . Furthermore, we have now included text in the discussion to address a possible link between the implication of LSD1 and JMJD3 in the regulation of BCL2 gene expression .
Minor comments (4) References in Introduction, at least regarding ER and breast cancer, seem somewhat random (many are not directly related to the statements and too many reviews are not sufficiently recent).
Response: We have organized and updated the references in the introduction.
(5) Results, first subtitle: careful, it's not cancer but cancer cell lines (in fact, only one).
Response: We agree and we have changed the subtitle. Figure S4 and S5 lack standard deviations, and Figure S8 lacks any quantification. This should be included. Response: We have included statistical analysis throughout the manuscript and added missing standard deviations and quantification in supplemental data. Figure 2A should be part of the manuscript and not only limited to a list of overlapping genes.
The expression array data as described in
Response: This section (Figure 2 and S3) has been reorganized and clarified. Figure 2B, Response: It is important to mention that, in spite the fact that we grown the cells in steroiddeprived media, we still observed recurrent basal activation of the ER -regulated genes. The effect observed by the depletion of JMJD3 on the basal levels may be explained by a recurrent transcription of some of ER -target genes caused by residual estrogens in media (also as described by (Metivier et al., 2003) ). Please see also our response to Referee 1, comment 4 and Referee 2, comment 2 (and new Figure S4 ). Figure 2C , which I think could be removed.
In
This reviewer does not see the added value of
Response: This panel figure has been displaced from the Figure 2 of the manuscript to the Figure S3 , and the corresponding text has been simplified to follow the logic behind the selection of BCL2. Figure 3 are very convincing, but lack one set of data. I would like to see included in Figure 3 ChIPs of H3K27me1 and me2. Since JMJD3 converts H3K27me3, any loss of me3 signal should be explained by a gain of me1 and/or me2.
The experiments in
Response: The result for H3K27me1 was present in the original and revised manuscripts (as Figure 4A) . Figure 4A shows a loss of ERalpha ChIP signal after 45minutes. Other reports which are cited in this paper (Shang et al., 2000; Metivier et al., 2003) have shown convincingly strong ER ChIP signal at this timepoint. This inconsistency should be discussed.
7.
Response: We like to bring to the attention of the reviewer that the time course has been done in none amanitin synchronized cells as compared to the cited reports (Metivier et al., 2003; Shang et al., 2000) . Furthermore, technical differences and gene selection (TFF1 vs BCL2) may show some differences. Finally, our results follow closely the same kinetic of recruitment of ER at BCL2 promoter/enhancer regions as shown in Perillo et al. (Perillo et al., 2008) . Figure 4A ). The temporal resolution of the experimental setup simply does not allow such a statement to be made, even though Figure 4B and 4E do make such a conclusion tempting. I do feel that the statement as written here is stated to strong for the data at hand, and should be weakened.
The authors claim that there is no temporal difference observed between ERalpha and JMJD3 recruitment (
Response: We agree with this point and changes have been done in the text.
9. Figure 5 describes the clinical data, where TMAs were stained for Her2 and H3K27me3. Survival data should be included here. This is a very important point.
Response: Unfortunately, it is the only point that we have not been able to address in our revised manuscript. We do not have enough patient survival information from the TMA that we used in this study to be able to draw a significant survival curve or any conclusion, and are unable to obtain such data. However, we would like to point out that we used this data to show that H3K27 methylation is dramatically regulated in different types of breast cancer, in close relation with the staining of HER2. In other terms, this data was included in this part of the manuscript to explain why we investigated the relationship between H3K27 methylation and BCL2 gene expression in antiestrogen-resistant breast cancer cells.
Does the Akt inhibitor revert the resistance-phenotype of the LCC2 cells? A cell proliferation assay, including LCC2 and MCF7 cells, is needed to illustrate this.
Response: The results that we obtained show a slight decrease in LCC2 cell proliferation from the combined effect of the AKT inhibitor and tamoxifen when compared to the AKT inhibitor alone, as shown in the graph below. However, we decided to not include this result in the manuscript as it it is difficult to significantly conclude that the AKT inhibitor reverts the tamoxifen resistance phenotype. We used the AKT inhibitor as a tool to show that it is possible to revert the chromatin state at the BCL2 enhancer region, but not necessarily to revert the resistance phenotype. Since antiestrogen resistance is a complex phenomenon and many studies have investigated the implication of the Her2/PI3K/AKT pathway (Benz et al., 1992; Campbell et al., 2001; Shou et al., 2004; Stoica et al., 2003) , it was not in our intention to pursue this direction, but to focus on the regulation of H3K27 methylation, BCL2 regulation, and apoptosis.
Chemical inhibitors do not always tend to be fully specific. Key experiments with the LY294002 inhibitor should be reproduced with another Akt inhibitor.
Response: We agree with the reviewer's comment, however this inhibitor is relatively specific and the link between AKT and H3K27 methylation has previously been demonstrated (Bredfeldt et al., 2010; Cha et al., 2005) . Furthermore, this inhibitor was used mainly as a tool to restore functionality to EZH2 and re-establish tamoxifen responsiveness to the BCL2 promoter/enhancer configuration.
12. Figure 7 should get a proper figure legend, explaining the model.
Response: As suggested by the reviewer, figure legend has been expanded and improved.
Akt has been extensively reported to directly influence ERalpha through phosphorylation events on the receptor. Even though I think it's out of the scope of the paper to rule out possible direct effects of Akt on ERalpha through the use of ERalpha point mutants, a direct effect of Akt on ER activity and the possible implications for this paper should be discussed.
Response: We agree with this point and have included a discussion on this in the revised manuscript.
The reference 'Anderton et al.,' on page 20 lacks a year.
Response: We have made the correction for this reference.
have been resolved. Even though the paper would gain a lot of weight if survival data would have been included, the story is already of significant quality and novelty in its current state and well fit for EMBO J. There is still one thing I would like to see included in the supplemental data, as I already requested after the original submission: In Figure 2A , the overlap of E2-upregulated genes with shJMJD3-repressed genes is shown. In the first round of review, I asked the authors to include the full genelists of each subgroup somewhere in the paper. The reason for this request is that I believe that manuscripts should be fully transparent, with all data included and clearly depicted. Still, both the current version as well as the original version only include a list of genes which are shared by the two tested conditions (fig S3B) , while for the other two subgroups only the numbers are shown in Figure 2A (so not the identity of these genes). I would like to see these two lists included in the paper as supplemental data.
2nd Revision -authors' response 12 July 2011
We have now included the two lists of genes from the Figure 2A in supplemental data as asked by the referee #3 (data set 1 and 2). We also added a brief 'Author Contribution' statement and a 'Conflict of Interest' disclosure in the manuscript.
